Yan and colleagues have shown that tumor Glyc62GRP94 (i.e., GRP94 glycosylated at N62) can be selectively targeted over the physiologic GRP94 through therapeutics, such as PU-WS13 [134]. The gene discussed is HSP90B1; the disease is neoplasm.